$LIVN News

Neuromodulation Publishes Full 36-Month CORE-VNS Results Demonstrating Sustained and Increasing Benefits of LivaNova’s VNS Therapy for Drug-Resistant Epilepsy

LivaNova Publishes Results In Neuromodulation: Technology At The Neural Interface Regarding Its CORE-VNS Trial Of Its VNS Therapy Devices

LivaNova to Present at UBS, Wolfe, Stifel, and Jefferies Healthcare Conferences in November

LivaNova PLC (NASDAQ:LIVN): An Affordable Growth Candidate With Reasonable Valuation

LivaNova PLC (NASDAQ:LIVN): Strong Growth Meets a High-Quality Technical Setup

LivaNova (LIVN) Stock Looks Undervalued As Its 60% Three Year Run Continues

LivaNova (LIVN) Narrative Keeps Fair Value In Focus As Shares Cool

Barclays Initiates Coverage On LivaNova with Overweight Rating, Announces Price Target of $105

Operating Leverage and Product Innovation Drive LivaNova’s(LIVN) Sustained Profit Outlook

LivaNova to Announce Third-Quarter 2026 Results

LivaNova Director Trades $273K In Company Stock

LivaNova PLC (LIVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

LivaNova Director Sells 1,650 Shares for $131,500

LivaNova PLC (NASDAQ:LIVN) Combines Strong Growth With a Timely Technical Setup

LivaNova (NASDAQ:LIVN) Combines Growth and Reasonable Valuation

LivaNova to Present at Morgan Stanley and Baird Healthcare Conferences in September

Piper Sandler Reiterates Overweight on LivaNova, Raises Price Target to $90

LivaNova: Careful About The Valuation And Upside

LivaNova (NASDAQ:LIVN) Combines Strong Growth With a Promising Technical Breakout Setup

Ahmet Tezel Executes Sell Order: Offloads $876K In LivaNova Stock